Clovis Oncology (CLVS) : The bears are holding on to their shorts in Accenture Plc with 8 more days remaining for them to cover their positions. The bearish positions have increased from 8,378,294 on Jul 29, 2016, to 8,692,848, on August 15, 2016. Daily, 1,137,675 shares are traded, which shows the high interest of the traders in the stock. The net addition of short open interest is 314,554 shares, which is an increase of just 3.8%. The total short interest of 26.3% of the float indicates that there arent many bears on this stock at the current prices. The short interest information was released on Wednesday Aug 24th after the market close.
Clovis Oncology (NASDAQ:CLVS): The stock opened at $24.22 on Wednesday but the bulls could not build on the opening and the stock topped out at $24.90 for the day. The stock traded down to $21.85 during the day, due to lack of any buying support eventually closed down at $22.36 with a loss of -2.91% for the day. The stock had closed at $23.03 on the previous day. The total traded volume was 13,911,825 shares.
In a related news, The Securities and Exchange Commission has divulged that Mast Erle T, officer (Executive VP and CFO) of Clovis Oncology, Inc., had unloaded 3,000 shares at an average price of $104.18 in a transaction dated on November 2, 2015. The total value of the transaction was worth $312,540.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.